Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Editas Medicine (EDIT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 11.54% and -3.82%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Editas Medicine (EDIT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%
by Zacks Equity Research
Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Editas, Allergan Start Dosing in Early-Stage Eye Disease Study
by Zacks Equity Research
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates
by Zacks Equity Research
Editas (EDIT) misses on earnings and revenues in fourth-quarter 2019.
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -311.43% and -75.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Editas (EDIT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Editas (EDIT) stock based on the movements in the options market lately.
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
by Zacks Equity Research
Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.
Editas Medicine (EDIT) Is Up 6.66% in One Week: What You Should Know
by Zacks Equity Research
Does Editas Medicine (EDIT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Is Editas (EDIT) Up 28.7% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher
by Zacks Equity Research
Editas Medicine (EDIT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data
by Zacks Equity Research
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
by Zacks Equity Research
Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 9.59% and -6.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Editas Medicine
by Zacks Equity Research
Editas Medicine, Inc. (EDIT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Editas Inks Deal for Gene Editing Neurological Disease Drugs
by Zacks Equity Research
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
CRISPR Therapeutics Enters New License Agreement, Shares Up
by Zacks Equity Research
CRISPR Therapeutics (CRSP) looks to strengthen its CAR-T therapy programs through its agreement with KSQ Therapeutics.
Adverum Reports Data From Phase I Wet AMD Study, Stock Down
by Zacks Equity Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
ETFs Poised to Benefit from Gene Editing Revolution
by Sweta Jaiswal, FRM
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
Why Is Editas (EDIT) Down 5.5% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
by Zacks Equity Research
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Editas Medicine (EDIT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -16.95% and -61.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?